Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to $15.2 billion.

  • Astrazeneca's Receivables - Net rose 1699.81% to $15.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.2 billion, marking a year-over-year increase of 1699.81%. This contributed to the annual value of $15.2 billion for FY2025, which is 1699.81% up from last year.
  • Astrazeneca's Receivables - Net amounted to $15.2 billion in Q4 2025, which was up 1699.81% from $14.3 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Receivables - Net peaked at $15.2 billion during Q4 2025, and registered a low of $6.3 billion during Q1 2021.
  • Over the past 5 years, Astrazeneca's median Receivables - Net value was $11.1 billion (recorded in 2024), while the average stood at $10.8 billion.
  • Per our database at Business Quant, Astrazeneca's Receivables - Net soared by 7904.82% in 2021 and then crashed by 40.57% in 2024.
  • Astrazeneca's Receivables - Net (Quarter) stood at $9.6 billion in 2021, then grew by 9.09% to $10.5 billion in 2022, then rose by 15.26% to $12.1 billion in 2023, then increased by 6.98% to $13.0 billion in 2024, then grew by 17.0% to $15.2 billion in 2025.
  • Its last three reported values are $15.2 billion in Q4 2025, $14.3 billion for Q3 2025, and $14.2 billion during Q2 2025.